This page shows the latest SGLT inhibitor news and features for those working in and with pharma, biotech and healthcare.
The drug is a dual inhibitor of SGLT1 and SGLT2 and was thought to work by reducing glucose absorption in the gastrointestinal tract and glucose reabsorption by the kidneys, as well ... Issues surrounding the higher rate of diabetic ketoacidosis (DKA) in
drug. Steglatro is one of the competitors in the sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs, which are now becoming standard therapy in managing type 2 diabetes (T2D) patients in ... In the UK, the treatment is priced at £29.40 for 28 days,
Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel
Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... PIONEER 4 saw the enrolment of 711 people with type 2 diabetes
Victoza is the second drug to get a recommendation for improving cardiovascular outcomes in type 2 diabetics after Eli Lilly and Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin), which had ... Merck &Co failed to win FDA approval for a
Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The approval of Qtern is good news for patients who may benefit from
More from news
Approximately 1 fully matching, plus 21 partially matching documents found.
We love what we do and we think it shows.It shows in the work we do, the space we work...